Breast cancer survivor offers wisdom at Faulkner satellite center
Call 877-422-3324 today to make an appointment
Make your appointment or second opinion with Dana-Farber today to meet with an onsite specialist.
Can’t get to Boston? Explore our Online Second Opinion service to get expert advice from Dana-Farber oncologists.
Toll-Free Number866-408-DFCI (3324)
Discover the ways to give and how to get involved to support Dana-Farber.
Poet Richard Fox gains insight – and material – through cancer treatment
A family faces cancer in an unfamiliar city – with help
Choosing mastectomy or not: Studying young women's surgical choices
Jeff's targeted therapy has kept his advanced lung cancer at bay.
William Hahn, MD
Using a novel three-part screening process, scientists at Dana-Farber
Cancer Institute have identified a gene that is made inappropriately in
about a third of all breast cancers. The discovery, reached in
collaboration with researchers at Brigham and Women's Hospital (BWH) and
the Broad Institute of Harvard and MIT, is reported in the June 15,
2007, issue of the journal Cell.
Unlike breast cancer-susceptibility genes such as BRCA1 and BRCA2, the newly identified gene, called IKBKE,
is not inherited in a mutated form that increases the risk of
developing breast cancer at an early age. Rather, the mutation arises
during a woman's life, causing an overproduction of the IKBKE protein.
That, in turn, spurs cell growth and proliferation. The mutation is
found in 30-40 percent of all breast cancers, making it a prime target
for future drugs for the disease.
The method used to home in on the gene — a combination of three
existing experimental approaches — offers an elegant solution to one of
the major hurdles of genome-age research: how to sift through the
multitude of genes identified by advanced screening technology as
potential cancer-causers to find those with the most profound role in
the disease. As such, the new approach can be used to discover genes
associated with many types of cancers, the study's authors state.
"The genetic material within many human cancer cells is in such
disarray that there can be numerous gene mutations," says the study's
co-senior author, William Hahn, MD, PhD, of Dana-Farber, BWH, and the
Broad Institute. "Current technologies — particularly 'microarray'
sensors, which read the activity and changes in thousands of genes at a
time — enable us to locate dozens or even hundreds of gene abnormalities
in cancer cells. The challenge is to winnow this group to find the
genes most centrally involved in cancer initiation and maintenance.
"In the current study, we used several complementary approaches to
identify an important breast cancer gene," he continues. "Each method
helps 'filter' the information from the previous one, enabling us to
zero in on the strongest candidate."
Hahn and his colleagues focused on a class of proteins known as
kinases, which serve as molecular "starting guns" for chemical reactions
within cells. Overproduction of certain kinases has been linked to a
variety of cancers. To determine which, if any, kinases play a role in
breast cancer, investigators conducted a sequence of experiments to
refine their results.
They began with a cell protein called Ras, a courier of signals from
the cell surface to the interior. Abnormalities in Ras or its partner
proteins — including kinases — occur in the vast majority of
"epithelial" cancers, which, like breast cancer, arise in the lining of
bodily tissues. Ras transmits signals to a variety of "downstream"
proteins — among them, proteins called MEK or PI3K. When both of these
become active at the same time, cells become cancerous, investigators
The team then created a set of 354 human kinases and injected each
into normal epithelial cells to see if any mimicked PI3K's ability to
transform them into cancer cells. They found five that did.
To narrow this field, investigators conducted a second group of
screening procedures. Using a variety of genome-scale approaches, they
sought to determine if genes for any of the five kinases were unusually
abundant in cancer cells. They found extra copies of IKBKE, but not of the other genes — and correspondingly high levels of the IKBKE protein. This pointed to IKBKE's role as a breast cancer oncogene.
In the third part of the study, the investigators explored whether breast cancer cells depend on IKBKE
for survival. In an earlier study, they had used a technique called RNA
interference — whose discovery was recognized with the Nobel Prize in
Medicine and Physiology last year — which uses bits of genetic material
to systematically stile certain genes. With a high-throughput version of
this technique, they found that when IKBKE was switched off, the cancer cells tended to stop proliferating and died.
"This triple screening approach enabled us to study what happened to cells when IKBKE
was turned on and when it was shut off, and to take a global look at
the genetic alterations within breast cancer cell lines and tumors,"
Hahn says. "Integrating these techniques allowed us to identify a new
breast cancer oncogene and show that it plays a crucial role in the
formation and survival of tumors."
The discovery that mutated IKBKE helps sustain a sizable
percentage of breast cancers may spur the development of new treatments
for the disease, Hahn remarks. Drugs able to target the oncogene and
shut it down could offer an effective therapy for women whose tumor
cells harbor the mutation.
The three-stage approach to finding breast cancer genes may be used
in other forms of cancer as well, Hahn continues. "Our study provides a
framework for integrated genomic methods of oncogene discovery."
The lead authors of the study are Jesse Boehm, PhD, of Dana-Farber
and the Broad Institute, Jean Zhao, PhD, of Dana-Farber and BWH, and Jun
Yao, PhD, of Dana-Farber. Other senior authors are Thomas Roberts, PhD,
of Dana-Farber, Kornelia Polyak, PhD, of Dana-Farber and Brigham and
Women's Hospital, and Eric Lander, PhD, of the Broad Institute.
Co-authors are Laura Mulvey, Tomoko Hirozane-Kishikawa, David Hill, PhD,
and Marc Vidal, PhD, of Dana-Farber; Stanislawa Weremowicz, MD, and
Andrea Richardson, MD, PhD, of BWH; Sarah Sjostrom, Carly Stewart, Rhine
Shen, PhD, Lauren Ambrogio, and Greg Hinkle, PhD, of Dana-Farber and
the Broad Institute; So Young Kim, PhD, Ron Firestein, MD, PhD, Ian
Dunn, Levi Garraway, MD, PhD, Heidi Greulich, PhD, and Matthew Meyerson,
MD, PhD, of Dana-Farber, BWH, and the Broad Institute; and Jennifer
Grenier, PhD, and David Root, PhD, of the Broad Institute.
Financial support for the study was provided by the National
Institutes of Health, the Tisch Family Fund, a Breast Cancer Center of
Excellence award, a Claudia Barr award, a Women's Cancer Program award,
and a Department of Defense Breast Cancer Program award.
Dana-Farber Cancer Institute (www.dana-farber.org)
is a principal teaching affiliate of the Harvard Medical School and is
among the leading cancer research and care centers in the United States.
It is a founding member of the Dana-Farber/Harvard Cancer Center
(DF/HCC), designated a comprehensive cancer center by the National
Brigham and Women's Hospital (BWH) is a 747-bed nonprofit teaching
affiliate of Harvard Medical School and a founding member of Partners
HealthCare System, an integrated health care delivery network. BWH is
committed to excellence in patient care with expertise in virtually
every specialty of medicine and surgery. The BWH medical preeminence
dates back to 1832, and today that rich history in clinical care is
coupled with its national leadership in quality improvement and patient
safety initiatives and its dedication to educating and training the next
generation of health care professionals. Through investigation and
discovery conducted at its Biomedical Research Institute (BRI), BWH is
an international leader in basic, clinical and translational research on
human diseases, involving more than 800 physician-investigators and
renowned biomedical scientists and faculty supported by more than $400M
in funding. BWH is also home to major landmark epidemiologic population
studies, including the Nurses' and Physicians' Health Studies and the
Women's Health Initiative. For more information about BWH, please visit www.brighamandwomens.org.
The Broad Institute of MIT and Harvard was founded in 2003 to bring
the power of genomics to biomedicine. It pursues this mission by
empowering creative scientists to construct new and robust tools for
genomic medicine, to make them accessible to the global scientific
community, and to apply them to the understanding and treatment of
The Institute is a research collaboration that involves faculty,
professional staff and students from throughout the MIT and Harvard
academic and medical communities. It is jointly governed by the two
Organized around Scientific Programs and Scientific Platforms, the
unique structure of the Broad Institute enables scientists to
collaborate on transformative projects many scientific and medical
For further information about the Broad Institute, go to http://www.broad.mit.edu.